Home › Diffuse Large B-Cell Lymphoma › Virginia
Diffuse Large B-Cell Lymphoma clinical trials in Virginia
17 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in Virginia.
Cities in Virginia
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- University of Virginia Cancer Center, Charlottesville
- VCU Massey Comprehensive Cancer Center, Richmond
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06649812A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Virginia Commonwealth University Massey Cancer Center, Richmond
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Virginia Cancer Specialists, PC ( Site 8003), Manassas
- VCU Health Adult Outpatient Pavillion ( Site 0138), Richmond
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06890884A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- University of Virginia Cancer Center ( Site 0138), Charlottesville
- Virginia Cancer Institute ( Site 0148), Richmond
- Blue Ridge Cancer Care ( Site 0132), Roanoke
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06717347Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Virginia Cancer Specialists, PC, Fairfax
- Virginia Oncology Associates - Virginia Beach, Virginia Beach
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06806033Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- University of Virginia, Charlottesville
- Virginia Cancer Specialists, Fairfax
- Virginia Oncology Associates - Norfolk, Norfolk
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT06500273A Study of ARC-02 in B-cell NHL
- Massey Cancer Center, Richmond
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT07691606Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
- VCU Massey Comprehensive Cancer Center, Richmond
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT06536049Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Virginia Oncology Associates, Norfolk
- Virginia Commonwealth University-Massey Cancer Center, Richmond
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT05826535A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- University of Virginia Health System, Charlottesville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Virginia Oncology Associates, Norfolk
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT07188558Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
- University of Virginia Health System, Charlottesville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 10, 2026 · NCT05852717Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- University of Virginia Cancer Center, Charlottesville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 9, 2026 · NCT06015880Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- VCU Massey Comprehensive Cancer Center, Richmond
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 2, 2026 · NCT05633615Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
- Virginia Commonwealth University, Richmond
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jan 23, 2026 · NCT06846463Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 20, 2025 · NCT05890352A Study of NX-1607 in Adults With Advanced Malignancies
- University of Virginia, Charlottesville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2025 · NCT05107674From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.